Slide 1

Aims

1. Evaluate the

complete remission rate

of pembrolizumab combined

with ISRT as an alternative to HDT/ASCT in early stage rel/ref HL

patients

2. Determine the

single agent response rate

of pembrolizumab in this

population

3. Determine the

toxicity and 2-year EFS

with this strategy

4. Evaluate

biological markers of response and resistance:

1. Tumor and TME immune evasion markers

2. Development of anti-tumor T-cell clonal expansion

3. T-effector:T-reg ratio

4. Serum TARC